CYP19A1 and benign prostatic hyperplasia: 2019). Aromatase inhibitor‐treated mice can develop prostatic hypertrophy. Long‐term oestrogen deficiency may cause it (Shen, 2009; Cheboub et al. 2019). Hypoestrogenism leads to elevated blood cholesterol levels. Men with hypercholesterolaemia are at an increased risk of developing prostate cancer. Aromatase inhibitors raise cholesterol, which leads to amyloid deposition in the prostate lobes (McCloskey et al. 2007).